• Mashup Score: 7

    Individual registration is still open

    Tweet Tweets with this article
    • #ESMO23: with all science & education coming out of Madrid, make sure to use the #oncology hashtags to help you drill down & join the conversations relevant to you. Feel free to add any others in the comments below 👇 #OncTwitter https://t.co/0SCjGUa2iN https://t.co/AAkyGfELnp

  • Mashup Score: 0

    In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O’Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being associated with increased odds of treatment discontinuation. In the trial, patients with CLL received 28-day cycles of continuous ibrutinib or six 28-day cycles of chemoimmunotherapy with fludarabine, cyclophosphami

    Tweet Tweets with this article
    • Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL? https://t.co/D36te8eAzJ #leusm #hematology

  • Mashup Score: 1

    Published: October 16, 2023Updated: October 17, 2023Written by: Rob LevyMedically Reviewed By: Jia Luo, MDWhat is NUT carcinoma?  NUT carcinoma, formerly known as NUT-midline carcinoma, is a rare but very aggressive cancer that can develop anywhere in the body but usually starts in the head, neck, and lungs. It’s a squamous cell cancer — meaning … Read more

    Tweet Tweets with this article
    • Dana-Farber and its allied hospitals have one of the only clinical trial programs in the country dedicated to finding better treatments for NUT carcinoma. Learn more: https://t.co/IpunBZV2tu #NUTcarcinoma @Jia_Luo https://t.co/vqX3SQMj2h